Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report

Molecular sequencing after highly potent targeted gene inhibitors have suggested resistant tumors can display substantial heterogeneity. Among these various mechanisms of resistance, secondary mutations on targetable oncogenes have been identified. BRAF V600E, as a bypass mechanism on disease progre...

Full description

Bibliographic Details
Main Authors: Orion Valet, Aurélie Swalduz, MD, Maxime Boussageon, MD, Adrien Buisson, Virginie Avrillon, MD, Bénédicte Mastroïanni, MD, Maurice Pérol, MD
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:JTO Clinical and Research Reports
Subjects:
Case report
EGFR mechanism of resistance
BRAF mutation
Dabrafenib-trametinib combination
Leptomeningeal disease
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000515

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000515

Similar Items